RIL
KYMR icon

Rothschild Investment LLC’s Kymera Therapeutics KYMR Stock Holding History

Rothschild Investment LLC’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1K Buy
114
+5
+5% +$430 ﹤0.01% 1738
2026
Q1 		$9.08K Buy
109
+10
+10% +$792 ﹤0.01% 1735
2025
Q4 		$7.7K Buy
99
+4
+4% +$270 ﹤0.01% 1686
2025
Q3 		$5.38K Sell
95
-20
-17% -$902 ﹤0.01% 1677
2025
Q2 		$5.02K Buy
115
+70
+156% +$2.41K ﹤0.01% 1512
2025
Q1 		$1.23K Buy
45
+5
+13% +$182 ﹤0.01% 2216
2024
Q4 		$1.61K Sell
40
-15
-27% -$677 ﹤0.01% 1935
2024
Q3 		$2.6K Buy
55
+40
+267% +$1.77K ﹤0.01% 1591
2024
Q2 		$448 Buy
15
+10
+200% +$346 ﹤0.01% 2087
2024
Q1 		$201 Buy
+5
New +$179 ﹤0.01% 1735

Other funds holding KYMR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Rothschild Investment LLC's KYMR Position: Q2 2026 in Review

Rothschild Investment LLC increased its Kymera Therapeutics (KYMR) stake by 4.6% in Q2 2026, buying an estimated $430 and bringing the position to 114 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1738.

Rothschild Investment LLC first reported a position in KYMR in Q1 2024 and has held it in 10 quarters since. 93 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Rothschild Investment LLC held 114 shares of Kymera Therapeutics worth $13.1K as of Q2 2026.
  • Rothschild Investment LLC bought 5 Kymera Therapeutics shares in Q2 2026, an estimated $430.
  • Kymera Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #1738 holding.
  • Rothschild Investment LLC first reported a position in Kymera Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 93 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.